Press Releases

Date	Title and Summary	Additional Format
Jun 18, 2021	Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	PDF Version
Jun 14, 2021	Steven Schoch Elected to Arena Pharmaceuticals Board of Directors	PDF Version
Jun 09, 2021	Arena Pharmaceuticals Announces Orphan Drug Designation for Etrasimod for the Treatment of Eosinophilic Esophagitis (EoE)	PDF Version
Jun 08, 2021	Arena Pharmaceuticals Announces First Participant Randomized in Phase 2 Trial Evaluating Temanogrel in Coronary Microvascular Obstruction (cMVO)	PDF Version
Jun 03, 2021	Arena Pharmaceuticals Earns "A" Rating from MSCI ESG, a Leading Rating Agency for Sustainable Investments	PDF Version
May 19, 2021	Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	PDF Version
May 12, 2021	Arena Pharmaceuticals Earns Prime Status from ISS ESG, a Leading Rating Agency for Sustainable Investments	PDF Version
May 05, 2021	Arena Reports First Quarter Financial Results with Strong Cash Position and Continued Progress on Pipeline Over the Quarter	PDF Version
Apr 28, 2021	Arena Pharmaceuticals to Release First Quarter 2021 Financial Results and Provide Corporate Update on May 5	PDF Version
Apr 23, 2021	Arena Pharmaceuticals Presents Clinician and Patient Reported Outcomes Data from Phase 2b ADVISE Trial Evaluating Etrasimod in Adult Atopic Dermatitis During a Late-Breaking Session at American Academy of Dermatology VMX	PDF Version

Arena is a clinical stage pharmaceutical company that does not have any medicines or products approved for use by any health authority.

Breadcrumb